What is the efficacy of R-DHAP in the treatment of relapsed diffuse large cell lymphoma?

Updated: Jun 12, 2019
  • Author: Shipra Gandhi, MBBS; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Early evidence suggested that in germinal center B (GCB)-like DLBCL, the cell of origin has a better response to rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) than to rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) . [44]  Options for relapsed disease continued to make progress.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!